Skip to main content
A

AuroDerm

AuroDerm develops soft tissue fillers enhanced with micron-sized pure metallic gold implants. This patent-pending technology aims to improve the safety and stability of fillers while minimizing side effects.

Copenhagen, Denmark150+ followers
Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Product

Problem

Dermal fillers can introduce bacteria into the injection site, leading to infections and biofilm formation, even with hyaluronic acid-based fillers. Once a biofilm develops, the infection can become chronic and difficult to treat, potentially resulting in granuloma formation and emotional distress for patients. The increasing number of filler treatments is expected to correlate with a rise in unwanted side effects.

Solution

AuroDerm is developing a technology that enhances soft tissue fillers with micron-sized pure gold particles (μGold) to mitigate the risk of infections and biofilm creation. The μGold particles remain at the injection site and release gold ions, which exert an anti-inflammatory effect, preventing and suppressing biofilm formation. This approach leverages the oligodynamic effect of gold to improve the safety profile of dermal filler treatments. The μGold particles are designed to be large enough to remain at the injection site, where they can provide long-term efficacy.

Target Audience

The primary users are clinicians and patients seeking to improve the safety and efficacy of soft tissue filler treatments by reducing the risk of infection and biofilm formation.

Features

  • Utilizes micron-sized pure gold particles (μGold) with a specific size and shape for optimal efficacy and minimal sedimentation.
  • μGold particles release gold ions locally, providing an anti-inflammatory property to the filler.
  • Designed to minimize the risk of infections and biofilm formation associated with dermal fillers.
  • Compatible with FDA-approved non-permanent, hyaluronic acid-based soft tissue fillers.
  • Delivered as a dry powder that is mixed with the dermal filler by the clinician before administration.
  • International patent-pending status on its innovative features and characteristics.
This profile is AI-generated and may contain inaccuracies.